Asare C, Raymundo C, Chen J, Perez-Chada L, Tawa M, Thornton S, Ottevanger R, Scarisbrick J, Olsen E, Khan N, Kim EJ, Shinohara MM, Larocca C; International Dermatology Outcomes Measures Cutaneous Lymphoma Working Group Additional Members: Neha Mehta Shah, Jenny Park, Krithika Nayudu. Protocol for a mixed-methods modified Delphi study for the development of a core domain set to assess the health-related quality of life of patients with mycosis fungoides and Sézary syndrome in clinical trials. , BMJ Open, 16(2): 2026,e103498
Cohen LS, Adeuyan O, Margolis DJ, Kim EJ, Chung J. Medicare coverage of home phototherapy units for cutaneous T-cell lymphoma versus psoriasis. , J Am Acad Dermatol, 94(2): 2026,693-695
Rastogi S, Brown-Korsah J, Kim EJ Cutaneous T-cell Lymphoma , Taylor and Kelly's Dermatology for Skin of Color, 3rd Edition textbook
: 2026
Willemze R, Assaf C, Bagot M, Beylot-Barry M, Berti E, Busschots AM, Cerroni L, Climent F, Diercks G, Geskin L, Gniadecki R, Gru AA, Guenova E, Guitart J, Jansen P, Kempf W, Kim E, Kim YH, Koldijk M, Marschalkó M, Mitteldorf C, Molgó M, Muniesa C, KJ Neelis, Olsen E, Ortiz-Romer PLo, Papadavid E, Pimpinelli N, Pulitzer M, Quaglino P, Querfeld C, Quint K, Scarisbrick JS, Schrader AMR, Stadler R, Vermeer M, Wehkamp U, Whittaker S, Wobser M. European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders. , Br J Dermatol, 193(6): 2025,1090-1100
Kossenkov AV, Dawany N, Majumdar S, Chang C, Nichols C, Wysocka M, Piekarz R, Showe MK, Bates SE, Rook AH, Kim EJ, Showe LC. Cutaneous T-Cell Lymphoma: Yin-Yang Effects of Transcription Factors HLF and NFIL3 in Regulation of Malignant T-Cell Markers in the Context of HDAC Inhibitor Romidepsin Treatment. , Cancers, 17(14): 2025,2380
Marshall A, Kassim S, Brown-Korsah J, Raymundo C, Chang C, Hippe DS, Kim EJ, Shinohara MM. Black patients with Mycosis fungoides and Sézary Syndrome experience worse health-related quality of life: A cross-sectional study.
Journal of the American Academy of Dermatology 2025-05-01 , J Am Acad Dermatol., 92(5): 2025,1100-1102
Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. , J Am Acad Dermatol., 92(3): 2025,634-636
Elghawy O, Sussman JH, Yang AG, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome , JAMA Dermatol, 161(6): 2025,656-658
Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. , J Am Acad Dermatol: 2024
Villasenor-Park J, Chung J, Kim EJ Cutaneous B-cell Lymphomas/Cutaneous Oncology , Hematology Oncology Clinics, 38(5): 2024,1111
